NT5E and cancer: Based on these results, in order to achieve affective redirection of purinergic signaling while enhancing cancer targeting specificity, we are currently designing and characterizing a multi-functional CAR-NK cell which consists of a single chain antibody targeting CD73 alongside dual chimeric antigen receptor targeting, as a next-generation, single-agent immunometabolic therapy of solid tumors with NK cells.